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INTRODUCTION
Despite recent advances in diagnosis and treatment, com-
munity-acquired pneumonia (CAP) has been recognized as
a common and potentially lethal condition, especially in older
adults and those with co-morbid diseases (1). Current guide-
lines for the management of adult CAP recommend initial
empirical antimicrobial treatment (2-4). This approach is
based on microbial patterns derived from several large prospec-
tive epidemiological series in different geographic areas.
The etiology of CAP depends on the geographic area, the
study population, and the utilized microbiological laboratory
tests (2). In most studies, Streptococcus pneumoniae is the most
common etiology in adult patients with CAP (1-6). How-
ever, the etiology remains undetermined in 40-60% of cases
(2, 3). A major factor contributing to the unknown etiology
of CAP is the difficulty in identifying atypical pathogens:
Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella
species. Diagnostic testing for these pathogens is not routinely
performed since culture is difficult, time-consuming, and
requires significant expertise. Serological diagnosis based on
high acute antibody titers is quick but inaccurate, whereas
diagnosis using the paired serology approach is more accu-
rate but requires >2 week to perform. However, the impor-
tance of the atypical pathogens is highlighted by the increas-
ing frequency of atypical organisms recognized in recent years
with the development of more sensitive diagnostic techniques
(5, 7) and consideration of a macrolide in proper empirical
antimicrobial therapy (3, 8). 
In Korea, very limited number of studies have been under-
taken to identify atypical pathogens as a cause of CAP (9-11).
In this study, we performed a prospective study to characterize
atypical pathogens as a cause of CAP among adults patients
admitted to 5 teaching hospitals over a period of one year by
using diagnostic tests for nucleic acid, antigen and antibody
detection of M. pneumoniae, C. pneumoniae, and L. pneumophila.
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Atypical Pathogens as Etiologic Agents in Hospitalized Patients with
Community-Acquired Pneumonia in Korea: 
A Prospective Multi-Center Study
Local epidemiologic data on the etiologies of patients hospitalized with community-
acquired pneumonia (CAP) is needed to develop guidelines for clinical practice. This
study was conducted prospectively to determine the proportion of atypical bacterial
pathogens in adults patients hospitalized with CAP in Korea between October 2001
and December 2002. Microbiological diagnosis was determined by serology for anti-
bodies to Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneu-
mophila. Nucleic acid of M. pneumoniae and C. pneumoniae in respiratory samples
and Legionella antigen in urine samples were detected. The study population con-
sisted of 126 patients (71 males, 55 females), averaging 54.6 yr (SD± ±17.8), whose
paired sera were available. An etiologic diagnosis for atypical pathogens was made
in 18 patients (14.3%): C. pneumoniae 9 (7.1%), M. pneumoniae 8 (6.3%), and L.
pneumophila 3 patients (2.4%). Streptococcus preumoniae and other typical patho-
gens were isolated from 36 patients (28.6%). Of 126 patients, 16 (12.7%) were
admitted to intensive care unit and atypical pathogens were identified in 5 patients
(31.3%). Initial clinical features of patients with pneumonia due to atypical, typical
or undetermined pathogens were indistinguishable. We conclude that atypical pa-
thogens should be seriously considered in hospitalized patients with CAP, when
initiating empiric treatment in Korea.
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MATERIALS AND METHODS
Study design
This prospective study is the result of Korean subgroup
analysis of ASIA-CAP study which was performed in 8 coun-
tries from October 2001 to December 2002. This study was
conducted in 5 teaching hospitals located in Seoul and Kyungi
province, Korea between October 2001 and December 2002,
after prior approval from each Institutional Review Board.
Written informed consent was obtained from all patients or
their legal representatives before study enrolment. The study
was carried out in compliance with Good Clinical Practice,
including International Conference on Harmonization Guide-
lines and the Declaration of Helsinki.
Patients
The study population consisted of adult patients (≥16 yr)
hospitalized with CAP. All patients had clinical features and
radiological findings compatible to CAP. Inclusion criteria
were new infiltrates on chest radiography or consolidation that
could not be attributed to some other etiology and 3 or more
of the following signs and symptoms: cough, acute changes
in the quality of sputum (<10 epithelial cells and >25 poly-
morphonuclear leukocytes per low-power field in micros-
copy), documented fever (>38℃) or hypothermia (<36.1℃)
within the preceding 24 hr, rales, leukocytosis (>10×109/L
or >15% bands), malaise, myalgia or gastrointestinal symp-
toms. All eligible patients were required to undergo serologi-
cal tests on paired acute- and convalescent-phase sera, as well
as tests for Legionella antigen in urine and polymerase chain
reaction (PCR) on respiratory samples collected at baseline.
Patients with evidence of tuberculosis, nosocomial pneu-
monia, lung cancer, aspiration pneumonia, or bronchiectasis
were excluded from the study. Subjects who were HIV posi-
tive or who had been hospitalized within 2 weeks prior to
study enrolment were also excluded.
Microbiological tests
Conventional cultures of clinical samples obtained from
patients with CAP were performed at each hospital and addi-
tional samples were sent to the central laboratory of Korea
University Hospital for microbiological tests for atypical pa-
thogens. For the purpose of serological testing, blood samples
(5-8 mL) were collected aseptically and stored at -20℃until
convalescent sera were obtained after 2-8 weeks to be tested
simultaneously. Sputum, nasopharyngeal aspirates, bronchoal-
veolar lavage, and samples of pleural fluid suitable for PCR
analysis were stored in PCR buffer in 2 mL vials at -20℃
before testing. Urine samples were collected in sterile con-
tainers and stored at -20℃until testing.
Specific antibodies (IgG and IgM) to M. pneumoniae were
measured using a particle agglutination test (SERODIA
MYCO II, Fujirebrio Inc, Tokyo, Japan). A modified micro-
immunofluorescence (MIF) test (Focus Diagnostics Inc, Cypress,
CA, U.S.A.) using purified elementary bodies diluted in egg
yolk sac was used to measure specific IgG antibodies to C.
pneumoniae, and C. psittaci. Legionella antibodies were detected
by an indirect immunofluorescence antibody test (MarDx
Diagnostics Inc, Carlsbad, CA, U.S.A.) for IgG antibodies
to L. pneumophila serogroup 1 through 7.
PCR assays for the detection of M. pneumoniae and C. pneu-
moniae were performed as previously described with primers
targeting the p1 adhesin gene of M. pneumoniae (12) and the
16S rRNA gene of C. pneumoniae (13). The presence of a PCR
product of 463 bp or 209 bp on gel electrophoresis was con-
sidered indicative of infection with C. pneumoniae or M. pneu-
moniae, respectively.
For the qualitative detection of L. pneumophila serogroup 1
soluble antigen in urine, specimens were tested by a micro-
titer enzyme-linked immunosorbent assay (Biotest Legionella
Urine Antigen EIA; Biotest AG, Dreieich, Germany) accord-
ing to the manufacturer’s recommendation. 
Criteria for etiologic diagnosis of atypical pathogens
The following criteria were used to classify a diagnosis as
definitive: 1) a four-fold or greater rise in antibody titers for
M. pneumoniae, C. pneumoniae, or L. pneumophila between acute-
and convalescence-phase sera; and 2) detection of L. pneumo-
phila antigen in urine. A probable etiologic diagnosis was
based on the detection of mycoplasmal or chlamydial DNA
in respiratory secretions.
Statistical methods
Data were analyzed using SPSS version 10.0 (SPSS Soft-
ware, Chicago, IL, U.S.A.). The  2 or Fisher’s exact tests were
used to compare categorical variables and the ANOVA was
used to compare means of continuous data. Results were con-
sidered statistically significant when p<0.05. 
RESULTS
A total of 202 patients hospitalized with a diagnosis of CAP
were enrolled in this study. Paired sera were obtained from
126 patients and provided the basis for estimating the rates
of infection caused by the three atypical respiratory pathogens.
Failure to obtain paired serum samples on 76 patients was
mainly due to follow-up loss (59 patients). Other reasons were
failure to meet eligibility criteria (7 patients), tuberculosis
(4 patients), and death (6 patients). 
Table 1 summarizes the demographic data and clinical fea-
tures at baseline of the 126 patients analyzed. Seventy-one
patients were male and 55 were female. Forty-six patients604 J.W. Sohn, S.C. Park, Y.-H. Choi, et al.
(36.5%) were 65 yr or older. The mean age of the patients
was 54.6 yr (range, 16 to 86 yr) (SD, ±17.8); males were
slightly older than females. Forty-five patients (35.7%) had
at least one underlying disease with diabetes mellitus being
the most common (13.5%).
Etiologic diagnosis was achieved in 50 (39.7%) cases, and
remained unknown in 76 cases. Atypical pathogens were
identified in 18 patients (14.3%); 14 (11.1% of the total)
diagnoses were definitive. The most common pathogen was
C. pneumoniae (7.1%), followed by M. pneumoniae (6.3%), and
L. pneumophila (2.4%) (Table 2). C. psittaci pneumonia was
not found. In 9 cases with C. pneumoniae, 5 cases were diag-
nosed using serologic criteria with a four-fold or greater rise
in antibody titer and 4 cases by positive PCR in sputum sam-
ples. In 8 cases with M. pneumoniae, 5 cases were diagnosed
by the serologic criteria, one case by both serology and PCR
assay in sputum samples, and 2 cases by PCR assay alone.
Three patients with L. pneumophila pneumonia were diagnosed
by the serologic criteria. No cases were positive for urinary
antigen to L. pneumophila serogroup 1.
Routine bacterial cultures of sputum and blood were obta-
ined in 126 patients; 39 pathogens were isolated from 36
patients (28.6%). S. pneumoniae was isolated from 17 (13.5%)
cases. Other microorganisms isolated were Klebsiella pneumo-
niae (4), Pseudomonas spp. (4), Acinetobacter spp. (4), Streptococ-
cus spp. (4), Escherichia coli (2), Enterobacter spp. (2), Haemophilus
influenzae (1), and Staphylococcus aureus (1). Two or more pa-
thogens were identified in 7 patients: a combination of a typi-
cal pathogen plus an atypical pathogen (4 cases) and a combi-
nation of two typical pathogens (3 cases). 
Underlying diseases, symptoms, signs, and laboratory/radio-
logy parameters of were compared among patients’ groups
with atypical, typical, or unknown pathogens are shown in
Table 3. Cases with dual typical-atypical infections were ex-
cluded from the analysis. Clinical features and laboratory
parameters did not differ significantly among the three groups.
In addition, no differences were observed with respect to aty-
pical etiology between two age groups: ≥65 yr and <65 yr.
In 46 cases of ≥65 yr, atypical pathogens were identified in
7 (15.2%) cases: C. pneumoniae 4 (8.7%), M. pneumoniae 2
(4.3%) and L. pneumophila 2 (4.3%) cases. In 80 cases of <65
yr, atypical pathogens were identified in 11 (13.8%) cases: M.
pneumoniae 6 (7.5%), C. pneumoniae 5 (6.3%), and L. pneumophi-
la 1 (1.3%) case. C. pneumoniae was not detected in patients
<40 yr. All L. pneumophila cases were detected in patients >60
yr. C. pneumoniae and L. pneumophila were more frequently
found in patients with underlying diseases than those without
underlying diseases: 8.9% vs. 6.2% and 4.4% vs. 1.2%, res-
pectively. However, it was not statistically significant (p>0.05).
M. pneumoniae was more frequently identified in patients with-
Characteristic No. (%) of patients
Age, yr (mean±SD) 54.6±17.8
Sex
Male 71 (56.3)
Femle 55 (43.6)
Admitted to intensive care unit 16 (12.6)
Previous antibiotics treatment 28 (22.2)
Co-morbid illness
Bronchial asthma 5 (3.9)
Congestive heart failure 6 (4.8)
Chronic bronchitis 6 (4.8)
Diabetes mellitus 17 (13.5)
Hepatic disease 4 (3.2)
Impaired renal function 6 (4.8)
Cerebrovascular disease 5 (4.0)
Others 14 (11.1)
Previously healthy 81 (64.3)
Table 1. Demographic and clinical characteristics for the 126
hospitalized adult patients with community-acquired pneumonia
Typical
(n=32)
Atypical
(n=14)
Unknown
(n=76)
p
value
Age 53.03±17.9 51.14±17.08 55.11±17.99 0.692
Male 20 (62.5%) 8 (57.1%) 40 (52.6%) 0.637
Admitted to  5 (15.6%) 2 (14.3%) 6 (7.9%) 0.124
intensive care unit
Previous antibiotics  10 (31.3%) 3 (21.4%) 14 (18.4%) 0.295
treatment
Underlying disease 12 (37.5%) 5 (35.7%) 26 (34.2%) 0.947
Cough  30 (93.8%) 12 (85.7%) 72 (94.7%) 0.454
Productive cough 22 (68.8%) 9 (64.3%) 50 (65.8%) 0.722
Fever 27 (84.4%) 12 (85.7%) 70 (92.1%) 0.442
Chillness 24 (75.0%) 13 (92.9%) 62 (81.6%) 0.358
Pleuritic chest pain 10 (31.3%) 5 (35.7%) 20 (26.3%) 0.852
Dyspnea 11 (34.4%) 2 (14.3%) 31 (40.8%) 0.350
Malaise 15 (46.9%) 10 (71.4%) 39 (51.3%) 0.550
Myalgia 16 (50.0%) 8 (57.1%) 32 (42.1%) 0.763
Diarrhea 0 (0%) 0 (0%) 5 (6.6%) 0.206
Wheezing 1 (3.1%) 2 (14.3) 8 (10.5%) 0.361
Crakle on lung  28 (87.5%) 12 (85.7%) 58 (76.3%) 0.355
auscultation
Blood leukocytes  14.25±7.3 11.22±5.1 13.01±7.5 0.410
(×10
3 cells/ L)
Pleural effusion 2 (6.3%) 0 (0%) 3 (3.9%) 0.677
Bilateral involvement 5 (15.6%) 4 (28.6%) 18 (23.7%) 0.541
Table 3. Comparison of patients with atypical, typical and un-
known etiology of community-acquired pneumonia*
*2 cases had dual infections. 
*All dual typical-atypical infections were excluded from the analysis.
No. (%) of cases
Definitive Probable Total
Microorganism
M. pneumoniae 6 (4.8) 2 (1.6) 8 (6.3)
C. pneumoniae 5 (4.0) 4 (3.2) 9 (7.1)
L. pneumophila 3 (2.4) 0  3 (2.4)
C. psittaci 00 0
Total 14 (11.1) 6 (3.2) 18 (14.3)
Table 2. Atypical pathogens in the 126 cases of community-ac-
quired pneumonia with acute and convalescent sera*Atypical Bacterial Etiologies in Community-Acquired Pneumonia  605
out underlying diseases (8.6% vs. 2.2%, p>0.05).
Five cases (31.3%) out of 16 patients requiring admission
to the ICU had pneumonia caused by atypical pathogens:
C. pneumoniae (3 cases) L. pneumophila (1 case) and M. pneu-
moniae (1 case). All cases were diagnosed by the definitive
criteria. There were no statistical differences with respect to
atypical etiology between patients admitted the ICU and
general ward (p>0.05). 
DISCUSSION
In this study, we analyzed the atypical etiology of CAP in
adult patients treated in hospital, based on the precise criteria
of etiologic classification and the use of several diagnostic pro-
cedures that included serologic tests on paired sera, detection
of bacterial antigen in urine, and detection of nucleic acids
in sputum. Cases of atypical pneumonia have increasingly
been reported, particularly in studies that have applied sen-
sitive diagnostic methods (5, 7, 14-17). The proportion of
cases of atypical pneumonia in other pneumonia studies has
varied from 8% to 63% (18-21). The proportion of atypical
pathogens (14.3%) found in our study was comparable to that
reported previously in other studies on CAP in Korea (18.5%)
(10).
C. pneumoniae is a frequent cause of CAP in patients treated
in hospital, with rates ranging from 3.4 to 43% (20, 21), and
is also associated with severe CAP (2, 14, 22). In our study,
C. pneumoniae was the etiology for 6.3% of CAP, and was res-
ponsible for 18.8% of severe pneumonia requiring admission
to the ICU, that was slightly higher than that from other
studies (22, 23). All three cases of severe CAP with C. pneu-
monia met the criteria of definitive diagnosis; one patient had
chronic lung disease and 2 patients were previously healthy.
Of the 2 previously healthy patients, one patient had dual
infection with C. pneumoniae and a typical pathogen. Among
patients with C. pneumoniae pneumonia, underlying illness
was not present in 56.6%, and dual infection did not occur
in 66.7%. Therefore, we suggest that C. pneumoniae could be
the sole cause of CAP requiring hospitalization.
The incidence of M. pneumoniae in hospitalized CAP patients
varies from 0.8 to 29.2% according to the study population
(21). In this study, M. pneumoniae was identified in 7.1% of
patients with CAP, which was similar to the results from pre-
vious Korean studies (10). Although M. pneumoniae pneumo-
nia is more frequent among children and young adults (3),
our results shows no age predilection, suggesting that it can
occur in all age groups.
The incidence of Legionella as a cause of sporadic CAP varies
from 0.6 to 12.2% among cases requiring hospitalization,
depending on the geographic area and the diagnostic tech-
nique used (21). In this study, L. pneumophila was identified
in 2.4% of patients with CAP, which was similar to the result
from a previous Korean study (9). In other Korean studies, no
cases of Legionella pneumonia were found (10). In our study,
in addition to the 3 definitive cases with Legionella pneumo-
nia, 15 (11.9%) cases showed persistently high antibody titers
(≥1:256) in both acute and convalescent serum samples. These
data suggest that L. pneumophila might be the potential eti-
ology of CAP in Korea similar to western countries. There
were no cases with positive urinary antigen test, even when
serology for L. pneumophila was positive. Although previous
studies reported high sensitivity of the urinary antigen assay
for L. pneumophila serogroup 1, it has some limitations. The
differences in sensitivities were attributed initially to differ-
ences in the proportion of clinical material from pneumonia
patients with infection caused by L. pneumophila serogroup 1
versus infection caused by other serogroups (24). Moreover,
variation was attributed to the differences in clinical severity
of the diseases. While 40-53% of the urinary antigen tests
were positive in patients with mild Legionnaires’ disease, 88-
100% of the tests were positive in patients with severe Legion-
naires’ disease. Different urinary antigen assays have been re-
ported with different sensitivities for detecting other serog-
roups which ranged from 14 to 69% (25-27). Although cul-
ture for Legionella was not performed in this study and thus
identification of L. pneumophila serogroups was not possible,
three definitive cases with Legionella pneumonia could be pos-
tulated to have been due to non-L. pneumophila serogroup 1.
C. psittaci was not identified as a cause of CAP in this study.
Up until now, there have been no reports on C. psittaci pneu-
monia in Korea (10). We suggest that C. psittaci might be a
rare cause of CAP in adult population in Korea.
As reported in recent study (28), PCR assay seems to be
less sensitive than serological testing for diagnosing C. pneu-
moniae and M. pneumoniae. In addition, current problems with
PCR techniques include great variability due to differences
in sample collection and preparation methods, and amplifi-
cation procedures; there are no U.S. Food and Drug Admin-
istration (FDA)-cleared reagents for PCR for detecting M.
pneumoniae and C. pneumoniae (3, 16). Thus rapid diagnosis
for these pathogens still remains to be solved in the clinical
field.
In present study, 126 out of 202 patients enrolled were
analyzed for atypical pathogen identification. Fifty-nine pati-
ents were follow-up loss and not included for analysis because
second serum samples were missing. Thus, it is possible that
atypical pathogens were underestimated. In other studies,
however, the rates of paired serum sampling was much lower
rates of 31-44% than 62% in this study (7, 10) and it helped
increase the reliability of the data analyzed. It was not possi-
ble to determine the impact of atypical pathogens on mor-
tality because a second serum was not available for those six
deceased. Some of patients who died during the course of
pneumonia may also have aggravation of comorbid illness.
As our study included only hospitalized patients, further study
is needed to determine role of atypical pathogens in patients
who do not require hospital admission and could have been606 J.W. Sohn, S.C. Park, Y.-H. Choi, et al.
safely managed in their home.
Our study verified again that clinical presentation was not
useful in differentiating typical and atypical pathogens (29,
30). This study concluded that frequency of the atypical pa-
thogens among patients hospitalized with CAP does not dif-
fer remarkably between Korea and western countries. Atypical
pathogens should be taken into account when making guide-
lines of empirical antibiotic therapy for CAP in Korea.
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